Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal (GI) cancers.

Immunotherapy will become part of the treatment armamentarium in GI cancer, particularly colorectal cancer, says Lenz.

A US clinical trial indicated that Immunoscore is prognostically significant. It validated the presence of CD3 and CD8 cells in the tumor and in the invasive margin.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Immuno-Oncology

ESMO Gastrointestinal Cancers Congress

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers